Received date: February 01, 2017; Accepted date: February 20, 2017; Published date: February 25, 2017
Citation: He F, Kumar N, Marotta F, Singh B, Khokhlov AN, et al. (2017) Effect of an Integrated Nutraceutical Formula on Key Inflammatory Regulators in Subjects with Metabolic Syndrome Features: A Randomized, Double-Blind Study. Clin Pharmacol Biopharm 6:167. doi: 10.4172/2167-065X.1000167
Copyright: © 2017 He F, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Visit for more related articles at Clinical Pharmacology & Biopharmaceutics
About one fourth of all American adults and a bit less than one sixth of Europeans are reported to be affected by metabolic syndrome. Aging seem associated to a consistent increase of this phenomenon which is now clear to be associated with a low-grade pro-inflammatory cascade. Dyslipidemia is a characteristic factor involved in this multifaceted metabolic setting and this provides new avenues to non-chemical biopharmaceutical interventions. Eighty-two patients (66 males and 16 females, 38-69 as age range) with metabolic syndrome were selected randomly. Patients meeting inclusion criteria were advised to adhere to a standard balanced diet but no specific dietary calorie-restriction or life-style modifications. Two matched patients groups were assigned either to 1 tab/ dinner of drug A and another group received 1 tab/dinner of drug B, both for 3 months. Physicians and patients were blinded as for the content of the tablets except being aware that one being P3/GB-2016 while the other a looking alike placebo. A third group of 25 healthy, normal-weight subjects without any biochemical abnormalities served as control. The mean HbA1c level showed a trend decrease in group I at 3-month observation but this group showed a significant decrease of total and LDL cholesterol, non-HDL aliquot and triglycerides throughout the study period (p<0.05). Serum concentration of either MIP1α or MIF were significantly higher in dysmetabolic patients as compared to healthy control (p<0.01). Treatment with P3/GB-2016 proved to significantly decrease both parameters at 3-month observation (p<0.01). Whereas circulating levels of MCP-1 appeared showed a wide dispersion of data and appearing to be higher in those subjects with highest (n.s.). Overall, P3/GB-2016 seems to be an effective oral agent in controlling dyslipidemia and key regulatory modulator within the management of metabolic syndrome.
Dyslipidemia; Metabolic syndrome; Cardiovascular risk; Monacolin; Caviarlieri
Dyslipidemia is the most fundamental risk factor for atherosclerotic cardiovascular disease and its associated complications, being a major cause of premature death worldwide. Levels of lipids, particularly LDL cholesterol, increase slightly during aging process in men but also in women after menopause. On the other hand atherosclerosis is associated to high total cholesterol level increases even before it shows a clearly pathological value. This is to say that the subtle lipid abnormalities may be already affecting coronary and cerebrovascular arterial network. This is essentially due to a pattern of lipoprotein abnormalities-or atherogenic lipoprotein phenotype (high VLDL levels, high small LDL particles and low HDL-cholesterol). Although an over 30% decline in cardiovascular disease has been noted in the past 15 years , it still accounts for 1 out of every 3 deaths in US . Along this period, dyslipidemia has stepped on the front line as risk factor for cardiovascular disease. In this regard, the Cholesterol Treatment Trialists’ Collaborators has shown that a 1.0 mmol/l reduction in low-density lipoprotein cholesterol (LDL-C) brought about a 9% reduction in all-cause mortality and a quite remarkable 25% decrease in cardiovascular events, whatever the risk profile . Growing incidence of obesity  and diabetes [5-7] have also significantly affected the current pathophysiology of cardiovascular disease. Indeed, it is now well established that all the above conditions share a number of mechanisms within a complex metabolic picture which has come clear along fundamental studies such as Framingham Heart Study . As a matter of fact, metabolic syndrome has come to be an epidemic health care of large proportion affecting industrialized  but also developing  countries. It has been calculated that, given the present trend, at least 50% of people over 60 years old may be affected. This multifaceted syndrome is an insulin resistant condition comprising a spectrum of impairments such as hyperglycemia, hypertension, dyslipidemia and accelerated cardiovascular disease. In 2013 the American College of Cardiology/ American Heart Association, not without some internal disagreements, had defined four “statins benefit groups” in whom the risk reduction benefits would significantly outweigh the potential adverse events . However, in spite of a recent review, balancing pros and cons, sheds an overall reassuring opinion regarding the use of statins , the fact remains that other authors have pointed out some warnings about its controversial widespread use [13,14]. Indeed, besides the already well-reported and not infrequent cases of myopathy , some concern has been also raised about the possibility that statins may negatively affect glucose level. This had lead Food and Drug Administration (FDA) to issue a specific warning on labels of this drug (http://www.fda.gov/ForConsumers/ConsumerUpdates/ Ucm293330.htm). Furthermore, a recent work from the group of Serafini has highlighted the still underestimated issue of detrimental potential interaction between statins and some nutrients . Quite recently, several national and European agencies as well as collaborative research groups have also variably stratified patients in “high risk” and “low risk group . This would thus suggest that a large cohort of not “high risk” patients or those who have experienced side effects from the usage of statins may be amenable to different approaches, such as phytochemicals intervention [18-21]. While several of such studies with phytochemicals may suffer from methodological limitations, it is still worth reporting what stated by Marshal et al.  that “As the statin-cholesterol controversy shows, it is time to recognize the benefits of natural medicine (i.e., functional medicine) for disease prevention and the maintenance of optimal health and wellness”. This position holds particularly true when considering the expanding scenario of metabolic syndrome in younger age population [22,23] where dietary and life-style modifications are more liable to be implemented. In this regard, there have been a number of studies where nutraceuticals intervention has been understandably associate to other robust therapeutic factors such as weight loss program, gut microbiota modulators and physical exercise [24-26]. While this is appreciable and meets a rational strategy, on the other hand may blur the specific significativity of the nutraceuticals intervention per sè. After a series of positive in-house experimental studies, we planned this study aiming to use an integrated phytocompound (P3/GB-2016, batch n. 607090, containing per tablet the followings: fermented red yeast 200 mg, artichoke dry extract 500 mg, vitamin B12 0.83 mcg, vitamin B6 1.4 mg, vitamin B3 9 mg, coenzime Q10 50 mg, banaba dry extract 75 mg and folic acid 110 mcg, Cardionam®, Named SpA, Lesmo, Italy) in patients with clustered risk factors for metabolic syndrome in view of potential benefits on key inflammatory markers besides on the lipid profile as well [27,28].
Selection of patients
Information’s collected at the time of the first recruitment baseline evaluations comprised demographic data, personal and family medical history, alcohol and/or cigarette consumption and duration, oral contraceptive use and hormone replacement therapy.
Exclusion criteria: Patients with secondary hypertension, cardiomyopathy, liver or kidney function, cerebrovascular or neurodegenerative diseases. Moreover, grossly abnormal total cholesterol (>280 mg/dl or LDL >180 mg/dl) under established lipid lowering drugs, past or concurrent malignancies or ongoing insulin treatment were excluded as well. Alcohol consumption over 12 g/day represented further exclusion criteria.
Patients group: Eighty-two patients (66 males and 16 females, 38-69 as age range) with metabolic syndrome were selected randomly. Metabolic syndrome was diagnosed by NCEP ATP guidelines: Blood Pressure ≥140/≥90 mmHg Males >102 cm Waist Circumference Females >88 cm Triglycerides >150 mg/dl Males <40 mg/dl HDL Cholesterol Females <50 mg/dl Fasting Plasma Glucose >110 mg/dl (Table 1). Written informed consent was obtained from all subjects beforehand and the study met the ethical guidelines of the 1975 Declaration of Helsinki. The study was carried out in a randomised double blind placebo controlled fashion. All patients were kept on their usually prescribed oral hypoglycaemics and/or anti-hypertensive drugs) but without any anti-hyperlipidemic medications.
|Blood Pressure ≥ 140/ ≥ 90 mmHg||Blood Pressure ≥ 140/ ≥90 mmHg||Blood Pressure ≥ 140/ ≥ 90 mmHg|
|Waist Males >102 cm||Waist Males >102 cm||Waist Males >102 cm|
|Circtunference Females >88 cm||Circumference Females >88 cm||Circumference Females • 88 cm|
|Triglycerides >150 mg dl||Triglycerides >150 mg/dl||Triglycerides >150 mg/dl|
|HDL Cholesterol Males <40 mg/dl||HDL Cholesterol Males <40 mg/dl||HDL Cholesterol Males <40 mg/dl|
|Females <50 mg/dl||Females <50 mg/dl||Females <50 mg/dl|
|Fasting Plasma Glucose >110 mg/dl||Fasting Plasma Glucose >110 mg/dl||Fasting Plasma Glucose >110 mg/dl|
Table 1: NCEP ATP guidelines (Eckel RH, Cornier MA. Update on the NCEP ATP-III emerging cardiometabolic risk factors. BMC Med. 2014 Aug 26;12: 115).
Patients meeting inclusion criteria were advised to adhere to a standard balanced diet but no specific dietary calorie-restriction or life-style modifications (physical exercise) were attempted at this stage. Two patients groups were matched as for gender, duration of proven diagnosis and associated diseases (Table 2).
|Age (years)||49 ± 8||55 ± 9|
|BMI (kg/m2)||25.4 ± 3.2||24.6 ± 3.8|
|Fasting Blood Glucose (mg/dl)||98.8 ± 7.8||101.6 ± 6.7|
|Waist Circumference (mg/dl)||87.8 ± 10.5||96.6 ± 8.4|
|Triglycerides(mg/dl)||177.6 ± 12.6||183.6 ± 13.3|
|Total Cholesterol (mg/dl)||251.7 ± 22.2||258.5 ± 12.6|
|HDL- Cholesterol (mg/dl)||41.4 ± 3.2||44.2 ± 2.4|
|LDL- Cholesterol (mg/dl)||161.4 ± 10.3||158.6± 11.2|
|VLDL (mg/dl)||33.6 ± 4.7||34.1 ± 2.2|
Table 2: Demographic, anthropometric, biochemical and clinical characteristics of studied population.
One group received 1 tab/dinner of drug A and another group received 1 tab/dinner of drug B. Physicians and patients were blinded as for the content of the tablets except being aware that one being P3/ GB-2016 while the other a perfectly outside looking alike placebo. Both tablets were bearing a distinctive code number. Patients’ visits were scheduled weekly and seven tablets were provided on each visit. On every office visit, patients’ compliance was checked by counting remaining tablets and adherence to diet was also discussed. At the end of the whole study period, all the data along with code numbers was submitted to the statistician and after decoding, the patients were divided into group I (P3/GB-2016) and group II (placebo). A third group of 25 healthy, normal-weight subjects without any biochemical abnormalities served as control.
All anthropometric assessments were carried out by the same dedicated nurse. Weight was calculated to the nearest 0.1 kg by using a digital scale with subjects stepping on barefoot in light clothing. Waist circumference was measured to the nearest 1 mm with a flexible, nonelastic tape midway between the rib cage and the iliac crest at the end of a mild expiration. Body Mass Index (BMI) was calculated as follows: weight (kg)/height squared (m2). Brachial artery systolic and diastolic blood pressure was measured by a mercury sphygmomanometer on the right arm with the subject in a sitting position after at least a 5-min rest. Blood samples were collected in the morning (8 AM to 9 AM) after a 12 h overnight fast, blood was drawn into into pyrogen-free blood collection tubes tubes and total cholesterol and high-density lipoprotein (HDL) cholesterol and triglyceride were measured by enzymatic assay (Denka-BioTech & Science, Lipokit-07532, Japan). Low-density Lipoprotein (LDL) cholesterol was calculated by the Friedwald formula LDL-C: ¼ TC-(HDL-C+TG/5) . High-density lipoprotein-cholesterol was measured by a direct method (Wako Pure Chemical Industries, Osaka, Japan). Glucose, liver and renal function tests were performed by routine biochemistry (using the Hitachi 7800 Series autoanalyzer (Hitachi High-Technologies Corporation, Tokyo, Japan) as well.
Part of plasma obtained after centrifugation was also stored at -80°C in multiple aliquots until analysis. Baseline serum levels of macrophage chemoattractant protein 1 (MCP-1), Migratory Inhibitory Factor (MIF) and macrophage inflammatory protein-1α (CCL3/MIP-1α) were assayed by commercially available Elisa kits. Levels were measured by quantitative sandwich enzyme-linked immunosorbent assay (Quantikine, R&D Systems, and Minneapolis, USA) according to the manufacturer’s protocols. In particular, the assays were carried out with an OptEIA MIP-1α and MIF kit. The assayed, MIP-1α and MIF levels were derived from a standard curve using recombinant human MIP-1α and MIF and the SOFTmax curve-fitting program. The intraand inter-assay coefficients of variation for all chemokines were <10%. All samples were measured in duplicate and the average of the 2 values was used for final data analysis. The assay conditions were controlled, standardized and pre-optimized to ensure repeatability and reproducibility. Analyses were blinded to clinical diagnosis.
Statistical analysis was performed using the χ2 statistic or Fisher’s Exact Test for independence. Pairwise analysis was performed when appropriate. Two-tailed test of significance was used throughout. Correlations were assessed using linear regression analysis. Post hoc test with Bonferroni correction was used to compare post-treatment values against baseline ones. Data are presented as mean ± SD and the significance level for all tests was set at p<0.05.
After breaking the codes kept under custody in a separate country, it appeared that group I was the compound whereas group II was the placebo. In both groups during the three months, no adverse effect was reported. The mean BMI in both the treatment groups showed a trend decreased without any significant difference between the two (data not shown). The systolic blood pressure remained stable throughout the study, irrespective of any treatment (data not shown). Both groups showed a comparable mean fasting blood sugar at 1 and 3 months control. However, the mean HbA1c level showed a trend decrease in group II at 3-month observation (p<0.061 vs . group I) (Figure 1).
Figure 1: Effect of P3/GB-2016 vs. placebo on glucose metabolism. Group I (light blue), group II (dark blue) and healthy control (green). ap<0.01 vs. healthy subjects. No significant difference appeared between treatment group and placebo although the former showed a not significant trend decrease of HbA1c level.
There was no statistically significant difference in the other routine biochemical parameters (data not shown). As compared to baseline and group I, group II showed a significant decrease of total and LDL cholesterol starting from the first observation visit throughout the study period (p<0.05, Table 3). At 3-month observation, group II patients showed also a not significant trend increase of HDL (p<0.067 vs. baseline and group I) and a significant decrease of VLDL aliquot and triglycerides (p<0.05 vs. baseline and group I). The circulating levels of MCP-1 were not significantly higher in our population as compared to healthy subjects (176 ± 98.5 pg/ml vs. 146.4 ±.54.4 pg/g, p<0.07). However, it appeared a wide dispersion of data and when analysing separately those subjects with BMI higher than 27 (11 patients) this group gathered the highest MCP-1 absolute values (212.2 ± 32.3 pg/ml). Statistics was not feasible to analyse this parameter in this subgroup for the limited number. Serum concentration of either MIP1α or MIF were significantly higher in dysmetabolic patients as compared to healthy control (p<0.01, Figures 2 and 3). Treatment with P3/GB-2016 proved to significantly decrease both parameters (MIP1α reaching normal values) at 3-month observation (p<0.01 vs. baseline and vs. placebo-treated group).
Figure 2: Effect of P3/GB-2016 vs. placebo on MIP1α serum level. Group I (light blue), group II (dark blue) and healthy control (green). ap<0.01 vs. healthy subjects. bp<0.01 vs. baseline and group I. At the 3 months observation values recorded in P3/GB-2016–treated patients were comparable to those in healthy subjects.
Figure 3: Effect of P3/GB-2016 vs. placebo on MIF serum level. Group I (light blue), group II (dark blue) and healthy control (green). ap<0.01 vs. healthy subjects. bp<0.01 vs. baseline and group I. At the 3 months observation values recorded in P3/GB-2016–treated patients were comparable to those in healthy subjects.
|Group||I (placebo)||II (P3/GB-2016)|
|Triglycerides(mg/dl)||171.2 ± 11.2||133.2 ± 11.6*|
|Total Cholesterol (mg/dl)||251.7 ± 22.2||218.7 ± 17.4*|
|HDL-Cholesterol (mg/dl)||42.6 ± 3.6||47.7 ± 2.5|
|LDL-Cholesterol (mg/dl)||157.7 ± 8.9||118.8± 10.2*|
|VLDL (mg/dl)||33.2 ± 5.2||28.5 ±3.6*|
Table 3: Lipid metabolism profile in studied population: effect of P3/GB-2016 supplementation for 3 months. *p<0.05 vs. baseline and group I.
Current views indicate that about 25% of all American adults and around 15% of Europeans are estimated to suffer from metabolic syndrome . The age-related increased likelihood of having metabolic syndrome brings to a picture of 40% of people in their 60s to 70s suffering from it. The metabolic syndrome is associated with a low-grade pro-inflammatory setting that may partially account for its relationship with an increased cardiovascular risk. Moreover, a growing number of data highlights the concept that obesity per sè represents a further state of ongoing subtle chronic inflammation primarily mediated by immune cells, such as macrophages and T-lymphocytes. Such situation triggers the development of insulin resistance and associated metabolic comorbidities such as non-alcoholic fatty liver disease and type 2 diabetes mellitus. To the morbidity and mortality associated to the latter, there is often a concurrent factor represented by atherosclerosis , and this applies either to men  and women . Our study showed that P3/GB-2016 significantly improved the lipid profile as already shown by other authors but who also applied a more stringent dietary intervention , as it would understandably be advised. However, the present nutriceuticals, albeit in the absence of a synergistic dietary- and life-style-modification, proved to yield a significant improvement of lipid profile with a trend increase of HDL and a significantly lower serum level of triglycerides, LDL and of non- HDL which includes very-low-density lipoprotein (VLDL), VLDL remnants, intermediate-density lipoprotein, chylomicrons, chylomicron remnants and lipoprotein(a).
This action is likely to be due to the well-known property of red yeast  whose even far higher dosage has been confirmed to be safe and without muscle-toxicity when also checked at a cellular level . Added to this, a concomitant lipid-lowering effect is likely to have been played by artichoke extract [33,34] whose polyphenols moieties have been recently shown to possess an efficient gastrointestinal bioavailability in vitro  and also an anti-hypercholesterolemiainduced oxidative stress in liver and cardiac tissue in rats . Interestingly, this specific phyto-ingredient has been shown, when employed at higher dosages, to exert a cholesterol-lowering effect even in healthy athletes under high-intensity exercise . This property together with its flavonoids-related endothelial function protection by iNOS upregulation  shared most recently by corosolic acidcontaining banaba extracts  may widen its potential application. Moreover, although fasting glycaemia didn’t show any significant change during treatment, group I showed a trend improvement of HbA1c. Although not reaching a statistical significance, this seemingly more favourable glucose metabolism may be advocated for by the specific contribution of corosolic acid-rich banaba ingredient which has several experimental data [40,41] although limited clinical reports so far [42,43]. On the other hand, one has to consider that about 50% of our population were already on hypoglycaemic drug treatment and this may have blunted the distinctive effect of this promising phytoingredient.
As mentioned above, during such complex metabolic derangement process, amongst other processes, leukocyte recruitment and infiltration triggered by chemokines have a key regulatory role at all stages of atherosclerosis  and are also expressed in atherosclerotic lesions such as shown with CCL3/MIP1a . Recent investigations have unveiled a correlation among different aspects of metabolic syndrome and the most common markers of inflammation. A high correlation between CRP and Body Mass Index (BMI) has already been reported, followed by the indexes of insulin resistance-fasting insulin and insulin sensitivity . Interestingly, our supplementation proved to significantly decrease the blood levels of chemokines, such as MIP1α and MIF which are key regulators of the inflammatory cascade. In particular, MIF is a multifaceted unique inflammatory cytokine controlling either intracellular as well as extracellular functions [46,47] and affecting cellular signalling in health and disease  where it seems related to the development and progression of metabolic syndrome-associated cardiomyopathy [49-52]. As reported by Kim et al. , we also found out that the serum concentration of this cytokine was significantly higher in people with metabolic syndromerisk factor than in healthy control. However, unlike his study, we couldn’t find any significant gender difference, although our female population was limited.
MCP-1 level showed only a trend decrease under trial treatment. When selecting those patients with BMI above 27, this parameter showed the highest levels, however, no statistics could be applied for the limited number of such patients (11 patients). This finding is in agreement with the data from Kim et al.  who had shown that the circulating levels of MCP-1 were related to obesity and its links with obesity-related metabolic complications such as atherosclerosis and diabetes. Adipose tissue is nowadays clearly regarded as an “organ” and it is liable to get inflamed this leading to increased infiltration of macrophages and enhanced release of pro-inflammatory cytokines  affecting all body and also a metabolically-crucial organ such as pancreas, as recently pointed out in an elegant review from Catanzaro et al. . Thus, it is likely that the present nutraceutical intervention if applied to overweight-obese subjects, irrespective of any other overt associated disease, may beneficially affect a greater number of obesityrelated cytokines. We can hypothesize that these beneficial effects can be advocated for by the reported anti-inflammatory properties of either red yeast [57,58], corosolic-rich banaba extract [59,60] and artichoke [61,62] phyto-ingredients.
It can be concluded that the vitamin-polyherbal preparation P3/ GB-2016, is not only an effective and safe measure in controlling dyslipidemia but also crucial inflammatory markers of metabolic syndrome, beyond hsCRP. This result has to be taken in further consideration when bearing in mind that no other robust dietary or life style interventions were concurrently applied and that these patients were already under anti-hypertensive and hypoglycaemic drugs. This specific biochemical benefit on cyto- and chemokines has been partly reported in statin-using trials  and so the current study, to the best of our knowledge, is the first confirming the usefulness of well-designed nutraceuticals intervention on specific and detrimental cytokines panels.
Although statins in their pleiotropic properties occupy a definite role in the therapeutic armamentarium of dyslipidemias and associated risks, a number of controversial issues still exist [13,14,64]. Recent concern has been raised as for possible neurological adverse effects  while coenzyme Q10 has shown significant cytoprotective mechanisms for neuronal function and repair processes [66-68]. Given the cautions as above as well as the at times straightaway “medicalization” by physicians whatever the degree of lipid disorders, one may find in a rational nutraceutical a weapon to be deployed within a long-lasting dietary- and life-style intervention strategy also for preventative aims . These data appear to be substantially more clinical impacting than what we observed in recent times with a caviar derivative (Caviarlieri) which had no effect whatsoever on lipid profile and strictly-related adipose tissue-linked inflammatory markers, besides being probably an unaffordable compound in routine clinical practice .